Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
UNLABELLED: Bisphosphonates can increase bone mineral density (BMD) in children with osteogenesis imperfecta (OI). In this study of adults with OI type I, risedronate increased BMD at lumbar spine (but not total hip) and decreased bone turnover. However, the fracture rate in these patients remained...
Автори: | Bradbury, L, Barlow, S, Geoghegan, F, Hannon, R, Stuckey, S, Wass, J, Russell, R, Brown, M, Duncan, E |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
2012
|
Схожі ресурси
Схожі ресурси
-
The ROSI study (risedronate in adults with osteogenesis imperfecta type 1)
за авторством: Duncan, E, та інші
Опубліковано: (2005) -
The ROSI study (Risedronate in adults with osteogenesis imperfecta type 1): Improved BMD but high fracture rate persists.
за авторством: Bradbury, L, та інші
Опубліковано: (2006) -
Application of Orthopantomography in the Analysis of Bone Mineral Density in Patients with Osteogenesis Imperfecta
за авторством: Lara García-Boedo, та інші
Опубліковано: (2024-02-01) -
Changes of bone turnover markers and bone mineral density among postmenopausal Thai women with osteoporosis receiving generic risedronate
за авторством: Ammarin Suwan, та інші
Опубліковано: (2024-10-01) -
The Effects of Risedronate Therapy Combined With Vitamin D and Calcium on Biochemical Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporosis
за авторством: Hüsniye Koç, та інші
Опубліковано: (2004-12-01)